Adults
A new study on epilepsy patients treated at Jimma University Medical Center in Ethiopia has found that 45.5% of patients experience remission, with a median time to first remission of 38 months. Researchers used parametric shared frailty models to analyze the data, taking into account factors such as age,
Drug resistance
Researchers from Capital Medical University in Beijing, China have made significant findings in the field of epilepsy treatment, specifically regarding the long-term effectiveness and predictors of vagus nerve stimulation (VNS) in drug-resistant epilepsy (DRE) patients. A study published in Acta Epileptologica revealed that VNS effectively controls seizures, with effectiveness and
Drug resistance
Research has made significant strides in understanding the therapeutic potential of deep brain stimulation (DBS) in treating drug-resistant epilepsy (DRE). A review conducted by researchers at Iran University of Medical Sciences explores the efficacy of high-frequency stimulation (HFS) and low-frequency stimulation (LFS) in DBS, focusing on mechanisms, target selection, and
Drug resistance
Research has shown that epilepsy is a prevalent neurological disorder affecting more than 50 million individuals worldwide, characterized by seizures and often associated with complications such as cognitive impairments and an increased risk of sudden unexpected death in epilepsy (SUDEP). Despite advancements in pharmacological treatments, one-third of patients develop drug
Drug resistance
A recent study published in JAMA Neurology has established LITT using the NeuroBlate System as a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical's 1,000+ patient LAANTERN research initiative, analyzed data from 145 patients across
Drug resistance
Research from the Provincial Hospital suggests that approximately one-third of epilepsy patients suffer from drug-resistant epilepsy (DRE), a condition that poses significant challenges despite the availability of numerous antiepileptic drugs. In response to this issue, researchers have explored alternative approaches to treat DRE, including non-pharmacological methods such as surgery, neurostimulation,
Drug resistance
A landmark study published in JAMA Neurology has provided definitive evidence that the NeuroBlate System is a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical, drew from the company's 1,000+ patient LAANTERN research initiative and
Drug resistance
Researchers at Monteris Medical have announced a groundbreaking study published in JAMA Neurology, highlighting the effectiveness of their NeuroBlate System in treating drug-resistant mesial temporal lobe epilepsy (MTLE). The study, which drew from Monteris' LAANTERN research initiative, involved 145 patients across 15 U.S. institutions and demonstrated long-term seizure
Drug resistance
NeuroBlate, a minimally invasive laser interstitial thermal therapy (LITT) system, has been proven effective in treating drug-resistant epilepsy, according to a landmark study published in JAMA Neurology. The study, which analyzed data from 145 patients across 15 U.S. institutions, demonstrates that LITT using NeuroBlate is a safe, durable, and
Adults
A recent study on multimorbidity in adults with epilepsy has shed light on the alarming prevalence of chronic disease in this patient group. Conducted by researchers from the Perron Institute, the study aimed to examine the distribution of multimorbidity and describe the contributing comorbidity of somatic and psychiatric chronic conditions
Drug resistance
Research from Moldova State University has highlighted the behavioral differences between individuals with drug-resistant epilepsy and those with well-controlled epilepsy. A study published in Psihologie, a journal of the Association of Psychologists Practitioners, Moldova, analyzed 102 participants with epilepsy, finding statistically significant differences in aggression, hostility, and shyness between the
Epilepsy
Researchers from the Kennedy Krieger Institute have developed a new approach to initiating pharmacologic treatment for children and adolescents with epilepsy who present with comorbid neuropsychiatric symptoms. The framework provides practical, evidence-informed guidance on determining when medication is warranted, selecting medications, and monitoring treatment. This approach aims to optimize both
